CRS on the Classified Information Procedures Act
The Classified Information Procedures Act (CIPA) was enacted in 1980 to provide a mechanism for handling classified information that was likely to arise in criminal trials. The Act provided for the identification of such information, provisions for establishing its relevance and admissibility, and for introducing unclassified substitutions that could be openly discussed at trial.
The CIPA has figured prominently in numerous trials, most recently in the now-concluded case against two former officials of the American Israel Public Affairs Committee. It also serves as a possible model and inspiration for resolving other conflicts between national security secrecy and due process in civil cases, such as those involving state secrets.
“As Congress recognized when it passed the Classified Information Procedures Act, courts have many tools at their disposal to move litigation forward even when some of the evidence cannot be disclosed,” said Sen. Russ Feingold earlier this year in endorsing the State Secrets Protection Act (S.417).
A report on the CIPA, including discussion of its shortcomings and limitations, was prepared by the Congressional Research Service in 1989. That report has not been updated to include recent developments, and it has been withdrawn from distribution by CRS. A copy was obtained by Secrecy News.
See “Classified Information Procedures Act (CIPA): An Overview,” March 2, 1989.
The transition to a clean energy future and diversified sources of energy requires a fundamental shift in how we produce and consume energy across all sectors of the U.S. economy.
A deeper understanding of methane could help scientists better address these impacts – including potentially through methane removal.
While it is reasonable for governments to keep the most sensitive aspects of nuclear policies secret, the rights of their citizens to have access to general knowledge about these issues is equally valid so they may know about the consequences to themselves and their country.
Advancing the U.S. leadership in emerging biotechnology is a strategic imperative, one that will shape regional development within the U.S., economic competitiveness abroad, and our national security for decades to come.